Статья
Современное лечение больных с острым коронарным синдромом (ОКС) включает двухкомпонентную антитромбоцитарную терапию ацетилсалициловой кислотой и ингибитором рецепторов P2Y12 тромбоцитов. При этом у больных без высокого риска кровотечений предпочтение отдается прасугрелу и тикагрелору, действие которых более выражено, в меньшей степени зависит от метаболизма у конкретного больного и наступает быстрее, чем у клопидогрела. Частота применения ингибиторов гликопротеина IIb / IIIa рецепторов тромбоцитов (ИГ IIb / IIIa) существенно сократилась. Однако эти препараты остаются актуальными при проведении чрескожных коронарных вмешательств у пациентов с высоким риском коронарного тромбоза, массивным тромбом в коронарной артерии, при тромботических осложнениях процедуры, феномене «no-reflow». Внутривенный путь введения ИГ IIb / IIIa обеспечивает их эффективность у больных с затруднением приема или нарушением абсорбции пероральных препаратов. В обзоре представлены клинико-фармакологические характеристики различных ИГ IIb / IIIa, данные рандомизированных клинических исследований и регистров последних лет, оценивающих результаты их использования у больных с ОКС.
1. Capodanno D, Milluzzo RP, Angiolillo DJ. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. Therapeutic Advances in Cardiovascular Disease. 2019;13:175394471989327. DOI: 10.1177/1753944719893274
2. Centurión OA. Current Role of Platelet Glycoprotein IIb/IIIa Inhibition in the Therapeutic Management of Acute Coronary Syndromes in the Stent Era. Journal of Cardiology & Current Research. 2016;5(4):1–11. DOI: 10.15406/jccr.2016.05.00175
3. Safley DM, Venkitachalam L, Kennedy KF, Cohen DJ. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes. JACC: Cardiovascular Interventions. 2015;8(12):1574–82. DOI: 10.1016/j.jcin.2015.04.031
4. Sethi A, Bajaj A, Bahekar A, Bhuriya R, Singh M, Ahmed A et al. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarctiona meta-regression of randomized controlled trials. Catheterization and Cardiovascular Interventions. 2013;82(2):171–81. DOI: 10.1002/ccd.24653
5. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021;42(14):1289–367. DOI: 10.1093/eurheartj/ehaa575
6. Староверов И.И., Шахнович Р.М., Гиляров М.Ю., Комаров А.Л., Константинова Е.В., Панченко Е.П. и др. Евразийские клинические рекомендации по диагностике и лечению острого коронарного синдрома с подъемом сегмента ST (ОКСпST). Евразийский кардиологический журнал. 2020;1(30):4-77. DOI: 10.38109/2225-1685-2020-1-4-77
7. Tummala R, Rai MP. Glycoprotein IIb/IIIa Inhibitors.. In: StatPearls-Treasure Island (FL): StatPearls Publishing;2022.
8. Orzalkiewicz M, Hodson J, Kwok CS, Ludman PF, Giblett JP, George S et al. Comparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society). The American Journal of Cardiology. 2019;124(3):373–80. DOI: 10.1016/j.amjcard.2019.05.010
9. Schneider DJ. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists: Glycoprotein IIb-IIIa antagonists. British Journal of Clinical Pharmacology. 2011;72(4):672–82. DOI: 10.1111/j.1365-2125.2010.03879.x
10. Мазуров А.В. Антагонисты гликопротеинов IIb/IIIa при остром коронарном синдроме. Актуальные вопросы болезней сердца и сосудов. 2008;4:24-30
11. Mazurov AV, Pevzner DV, Antonova OA, Byzova TV, Khaspekova SG, Semenov AV et al. Safety, inhibition of platelet aggregation and pharmacokinetics of F(ab′) 2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in highrisk coronary angioplasty. Platelets. 2002;13(8):465–77. DOI: 10.1080/0953710021000057839
12. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393
13. Zeymer U, Margenet A, Haude M, Bode C, Lablanche J-M, Heuer H et al. Randomized Comparison of Eptifibatide Versus Abciximab in Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2010;56(6):463–9. DOI: 10.1016/j.jacc.2009.08.093
14. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 1998;339(7):436–43. DOI: 10.1056/NEJM199808133390704
15. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISMPLUS) Study Investigators. Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction. New England Journal of Medicine. 1998;338(21):1488–97. DOI: 10.1056/NEJM199805213382102
16. Topol EricJ, Califf RobertM, Weisman HarlanF, Ellis StephenG, Tcheng JamesE, Worley S et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months. The Lancet. 1994;343(8902):881–6. DOI: 10.1016/S0140-6736(94)90007-8
17. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann F-J et al. Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials. JAMA. 2005;293(14):1759–65. DOI: 10.1001/jama.293.14.1759
18. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients’ data with long-term follow-up. European Heart Journal. 2007;28(4):443–9. DOI: 10.1093/eurheartj/ehl472
19. Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER. A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention: A Meta-Analysis of Contemporary Randomized Controlled Trials. Circulation: Cardiovascular Interventions. 2009;2(3):230–6. DOI: 10.1161/CIRCINTERVENTIONS.108.847996
20. Ottani F, La Vecchia L, De Vita M, Catapano O, Tarantino F, Galvani M. Comparison by Meta-Analysis of Eptifibatide and Tirofiban to Abciximab in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. The American Journal of Cardiology. 2010;106(2):167-174.e1. DOI: 10.1016/j.amjcard.2010.03.012
21. Simoons ML, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The Lancet. 2001;357(9272):1915–24. DOI: 10.1016/S0140-6736(00)05060-1
22. Beavers CJ, Jennings DL. Use of Glycoprotein IIb/IIIa Inhibitors in the Modern Era of Acute Coronary Syndrome Management: A Survey of Cardiovascular Clinical Pharmacists. Journal of Pharmacy Practice. 2021;34(3):372–7. DOI: 10.1177/0897190019872386
23. Montalescot G, van ’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L et al. Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine. 2014;371(11):1016–27. DOI: 10.1056/NEJMoa1407024
24. de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Urban D et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clinical Research in Cardiology. 2015;104(9):727–34. DOI: 10.1007/s00392-015-0835-2
25. Zwart B, Yazdani M, Ow KW, Richardson JD, Iqbal J, Gunn JP et al. Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets. 2020;31(2):174–8. DOI: 10.1080/09537104.2019.1665642
26. Saleiro C, Teixeira R, De Campos D, Lopes J, Oliveiros B, Costa M et al. Glycoprotein IIb/IIIa inhibitors for cardiogenic shock complicating acute myocardial infarction: a systematic review, meta-analysis, and meta-regression. Journal of Intensive Care. 2020;8(1):85. DOI: 10.1186/s40560-020-00502-y
27. De Felice F, Tomassini F, Fiorilli R, Gagnor A, Parma A, Cerrato E et al. Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock. Circulation Journal. 2015;79(7):1568–74. DOI: 10.1253/circj.CJ-15-0053
28. Blanchart K, Heudel T, Ardouin P, Lemaitre A, Briet C, Bignon M et al. Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre‐treated with newer P2Y12 inhibitors. Clinical Cardiology. 2021;44(8):1080–8. DOI: 10.1002/clc.23654
29. Эрлих А.Д., Грацианский Н.А. Российский регистр острого коронарного синдрома «РЕКОРД-3». Характеристика пациентов и лечение до выписки из стационара. Кардиология. 2016;56(4):16-24. DOI: 10.18565/cardio.2016.4.16-24